NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical ...
February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has ...
来自MSN2 个月
Concerns raised over a lack of subacute care in Saskatchewan health care
"We take patients from hospital who are subacute, transition them to our facility, where we can provide holistic wraparound care that better meets the needs of that population," said Katelyn ...